Dianthus Therapeutics
DNTH
84.55
-0.28
-0.33%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.55
-0.28
-0.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 15 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.1 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 128.97% +2.10pp
- Institutions
- 347 +15
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund85.15%
Hedge Fund29.53%
VC/PE Fund10.19%
Public Company1.36%
Private Company0.99%
Sovereign Wealth Fund0.75%
Insurance Company0.37%
Government Pension Fund0.36%
Endowment Fund0.26%
Individual/Insider0.15%
Top holders as of 2026-09-30
FMR
15.19% · 8.55M sh
T. Rowe Price Group, Inc.
11.78% · 6.63M sh
BlackRock
7.80% · 4.39M sh
Wellington Management Group
5.74% · 3.23M sh
Fairmount Funds Management LLC
4.51% · 2.54M sh
State Street Global Advisors
4.50% · 2.53M sh
Vanguard Capital Management, LLC
4.31% · 2.43M sh
Avidity Partners Management, L.P.
3.74% · 2.10M sh
Octagon Capital Advisors LP
3.27% · 1.84M sh
TCG Crossover Management, LLC
2.98% · 1.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Marino Garcia | Chief Executive Officer | 0.12% |
| Adam Veness | Senior Vice President | 0.03% |
| Simrat Randhawa | Executive VP and Head of R&D | 0.01% |
| Alison Lawton | Independent Chairperson | -- |
| Sujay Kango | Independent Director | -- |
| Anne McGeorge | Independent Director | -- |
| Edward Carr | Chief Accounting Officer | -- |
| Jonathan Violin | Independent Director | -- |
| Steven Romano | Independent Director | -- |
| Paula Soteropoulos | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | Derivative Exercise and Sale | -124,042 | $8.44–91.59 |
| 2026-11-08 | Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | Intent to Sell (Form 144) | -124,042 | $86.03 |
| 2026-09-16 | Edward Carr | Chief Accounting Officer | Derivative Exercise and Sale | -20,000 | $17.88–104.39 |
| 2026-08-31 | Simrat Randhawa | Executive VP and Head of R&D | Derivative Exercise and Sale | -23,124 | $17.88–106.74 |
| 2026-08-18 | Simon Read | Independent Director | Derivative Exercise and Sale | -2,778 | $18.36–117.55 |
| 2026-08-12 | Adam Veness | Senior Vice President | Derivative Exercise and Retained | +15,000 | $18.17 |
| 2026-08-09 | Anne McGeorge | Independent Director | Derivative Exercise and Sale | -7,750 | $11.20–111.41 |
| 2026-08-09 | Simon Read | Independent Director | Derivative Exercise and Sale | -2,777 | $18.36–111.77 |
| 2026-08-09 | Adam Veness | Senior Vice President | Derivative Exercise and Sale | -20,000 | $17.88–111.18 |
| 2026-08-06 | Marino Garcia | Chief Executive Officer | Derivative Exercise and Sale | -166,000 | $8.44–110.76 |
| 2026-07-08 | Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer | Derivative Exercise and Sale | -31,249 | $21.77–101.97 |
| 2026-06-16 | Adam Veness | Senior Vice President | Derivative Exercise and Sale | -30,000 | $17.88–81.38 |
| 2026-05-31 | Simrat Randhawa | Executive VP and Head of R&D | Derivative Exercise and Sale | -26,530 | $8.44–91.37 |
| 2026-05-20 | Alison Lawton | Independent Chairperson | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Sujay Kango | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Anne McGeorge | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Jonathan Violin | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Steven Romano | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Paula Soteropoulos | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
| 2026-05-20 | Simon Read | Independent Director | Other Derivative Acquisition | +6,090 | $89.63 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.
Dianthus Therapeutics discussion 0 comments